About Us
Building on Decades of Immunology Research
Nefro Avillion is a clinical-stage biotechnology company headquartered in New York, USA. Founded in 2025, the company is dedicated to developing novel immunomodulatory therapies for patients with serious conditions where the immune system plays a central role in disease.
Our lead asset, siplizumab (also known as TCD601), is a humanised IgG1κ monoclonal antibody that binds to the human CD2 receptor found on T cells and natural killer (NK) cells. Siplizumab has demonstrated a unique profile of immunomodulatory effects, selectively suppressing the function of T and NK cells while enriching regulatory T cell populations.
Nefro Avillion was established to build on an extensive foundation of published clinical research and advance siplizumab through rigorous clinical development programmes across multiple high-unmet-need indications.
779+
Subjects treated to date
20+
Years of clinical data
9
Active clinical programmes
To develop and deliver transformative immunomodulatory therapies that improve outcomes for patients undergoing organ transplantation and those living with serious autoimmune and neurodegenerative diseases.
– Nefro Avillion Clinical DevelopmenT
Meet The Team
Allison Jeynes
Anna Danilewicz
